-
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Tuesday, June 29, 2021 - 12:29pm | 394Read More...Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King initiated coverage of Regeneron shares with a Buy rating and a $703 price target. The...
-
Why Intellia Therapeutics Stock Is Soaring Today
Monday, June 28, 2021 - 8:49am | 410Read More...Intellia Therapeutics Inc (NASDAQ: NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported positive interim data from an ongoing Phase...
-
Upside Of 124% Expected For Akebia Therapeutics Following Vadadustat Collaboration
Wednesday, April 26, 2017 - 10:10am | 308Read More...Analysts at JMP Securities believe Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that develops therapeutics based on hypoxia-inducible factor (HIF) biology, could deliver investors a triple-digit percentage return. JMP's Michael King maintains an Outperform rating on Akebia's...
-
Exclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate
Thursday, April 20, 2017 - 2:15pm | 1282Read More...Idera Pharmaceuticals Inc (NASDAQ: IDRA) is a clinical stage biotech that has recently re-focused its pipeline to focus on oncology, starting with melanoma. The company has seen its share price rise 50 percent in 2017. In March, JMP Securities initiated coverage of the company at Market Outperform...
-
Idera Pharma Shares Could Be A Four-Bagger, JMP Says
Wednesday, March 22, 2017 - 9:08am | 264Read More...Idera Pharmaceuticals Inc (NASDAQ: IDRA) is a clinical-stage biopharmaceutical company developing novel nucleic acid-based product candidates for the treatment of cancer and rare diseases. The company is “capable of generating a host of promising drug candidates,” JMP Securities’...
-
Here's One Biotech Stock JMP Analysts Are Very Bullish On
Wednesday, August 26, 2015 - 9:31am | 310Read More...Biotech stocks are among the most volatile and investors are constantly looking towards Wall Street for top notch research and analysis. Michael King of JMP Securities hosted an investor call with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s management team and discussed revusiran...
-
Stifel, JMP Securities Discuss What To Expect From AAIC Conference
Monday, July 20, 2015 - 8:30am | 464Read More...In a report published Monday, JMP Securities analyst Michael King discussed the potential upside for the biotech sector ahead of the upcoming Alzheimer's Association International Conference (AAIC) that will take place July 18 through July 23 in Washington, D.C. King noted various media...
-
JMP Securities Covers Mostly Good News From Pharma Pending More Visibility
Wednesday, February 11, 2015 - 8:54am | 451Read More...Achillion Pharmaceuticals Inc.'s (NASDAQ: ACHN) recent interim data for its developmental hepatitis C drug is "incrementally positive," according to JMP Securities' Liisa A. Bayko. Achillion's Monday data dump is among a half-dozen drug company developments that JMP analysts commented on Tuesday....
-
UPDATE: JMP Securities Reiterates Coverage on ARIAD Pharmaceuticals, Sees Market Share Regain
Monday, January 13, 2014 - 12:51pm | 118Read More...In a report published Monday, JMP Securities analyst Michael King reiterated Market Outperform on ARAID Pharmaceuticals, Inc. (NASDAQ: ARIA), with a $10.00 price target. According to the report, ARIA is gearing up to recapture market share in both the T315I and later-line CML market with a...
-
UPDATE: JMP Securities Reiterates Market Perform on Alnylam Pharmaceuticals on Therapeutic Candidates
Monday, January 13, 2014 - 11:32am | 158Read More...In a report published Monday, JMP Securities analyst Michael King reiterated Market Perform on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), with a $68.00 price target. According to the report, “Development of ALNY RNAi therapeutic candidates is progressing ahead of prior guidance; reiterate...
